Treatment Approach for Catheter-Associated UTI with Prior Pseudomonas

Rationale for Current Cefepime Therapy

The European Association of Urology strongly recommends against using fluoroquinolones in patients from urology departments or those who have used fluoroquinolones in the last 6 months, making cefepime the optimal empiric choice for catheter-associated UTI with prior Pseudomonas infection 2, 3, 4
Cefepime is the optimal empiric choice for catheter-associated UTI with prior Pseudomonas infection because it provides robust coverage against Pseudomonas aeruginosa and other gram-negative organisms commonly implicated in catheter-associated infections 2, 3, 4

For this catheter-associated complicated UTI, 7-10 days of antimicrobial therapy is recommended since the catheter was exchanged in the emergency department 1
If the catheter must remain in place long-term, consider extending therapy to 14 days 1
The catheter exchange performed in the ED was the single most important intervention for resolving catheter-related UTI 1
For male patients with complicated UTI where prostatitis cannot be excluded, 14 days of therapy is recommended 2, 3

Once final culture and susceptibility results are available, therapy should be targeted to the specific pathogen 1
A repeat urine culture from the newly exchanged catheter should be obtained if clinical response is inadequate within 48-72 hours 1

Monitor clinical response within 48-72 hours of initiating cefepime therapy 1
If fever persists beyond 72 hours of appropriate therapy, evaluate for complications such as abscess, obstruction, or other metastatic sites of infection 1

Transition to oral antibiotics is appropriate once the patient has been hemodynamically stable and afebrile for at least 48 hours 2, 3
For Pseudomonas infections with documented ciprofloxacin susceptibility, oral ciprofloxacin 750mg twice daily can be used to complete the treatment course 5, 6

Do not use ciprofloxacin empirically in this patient despite prior Pseudomonas susceptibility, as recent fluoroquinolone exposure (within 6 months) is a strong contraindication per European Association of Urology guidelines 2, 3, 4
Avoid prophylactic antimicrobials at the time of future catheter changes as this practice is not recommended and may promote resistance 1
Do not treat asymptomatic bacteriuria if it occurs after completion of therapy, as this is common in patients with chronic indwelling catheters and does not require treatment unless symptomatic 2, 4, 7

Combination therapy with an aminoglycoside is not routinely recommended for catheter-associated UTI unless the patient has septic shock or concern for extensively drug-resistant organisms 2, 3
Future catheter-associated infections should prompt consideration of alternative catheter management strategies, including intermittent catheterization if feasible, given the high risk of recurrent infection with chronic indwelling catheters 2, 4